Summary by Moomoo AI
Avalo Therapeutics, Inc., a biotechnology company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, is a standard procedure for companies preparing for upcoming shareholder meetings where proxy materials are provided to shareholders. Avalo Therapeutics confirmed that no filing fee was required for this submission. The materials filed are intended to provide shareholders with additional information ahead of the company's decision-making process.